Roche CEO Schwan Speaks as Drugmaker Boosts Outlook for Third Time

The transcript covers an interview with Roche's CEO, Severin Schwan, discussing the company's strong business performance, particularly in the third quarter, driven by new medicines for severe diseases. It addresses the impact of biosimilars on European sales and the anticipated effects in the US. The conversation also touches on the ongoing deal with Spark Therapeutics, regulatory challenges, and potential US tariffs on Swiss medicines. Schwan emphasizes the importance of innovation and the need for reform in US healthcare to reduce high out-of-pocket expenses for patients.

What concerns do regulators have regarding Roche's hemophilia business?

What are Roche's views on the pricing control attempts in the United States?

What does Roche believe is necessary to reduce out-of-pocket expenses for patients in the United States?